Orexigen’s New Data (NASDAQ:OREX)
Jyotsna Ramani (October 28th, 2009) Writes:
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has announced and presented their new data from the COR diabetes trials for Contrave to expand on top line results announced in July this year. This new data shows that after completing 56 weeks of therapy, Contrave patients have lost weight significantly and improved on important markers of cardiometabolic risk. Though it was good news for investors and analysts, shares dropped a bit and showed no signs of moving upward. The new data was presented during the panel discussion at the 27th Annual Scientific Meeting of The Obesity Society.
Obese patients have a higher risk of developing cardiovascular disease and diabetes. After the Contrave trials patients demonstrated significant improvements in their waist circumference, HDL and triglycerides. Patients with Type 2 diabetes taking Contrave saw a
...

![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)




